Rigel’s fostamatinib successfully meets endpoint in chronic ITP trial
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261)...